Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration

被引：1
|
作者：
Shao, Y-Y. [1 ]
Chen, B-B. [2 ]
Lin, Z-Z. [3 ]
Hsu, C-H. [1 ]
Wang, M-J. [3 ]
Cheng, A-L. [1 ]
Hsu, C. [1 ]
机构：
[1] Natl Taiwan Univ NTU, Grad Inst Oncol, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Radiol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw371.99
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)
    Qi, Qi
    Liu, Yang
    Li, Rentao
    Liu, Yayue
    Zhang, Xihao
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma A systematic review and meta-analysis
    Shen, Yunzhi
    Bai, Yu
    MEDICINE, 2025, 104 (04)
  • [33] A Phase II Trial of Second-Line Axitinib Following Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma
    McNamara, Mairead G.
    Le, Lisa W.
    Horgan, Anne M.
    Aspinall, Alex
    Burak, Kelly W.
    Dhani, Neesha
    Chen, Eric
    Sinaei, Mehrdad
    Lo, Glen
    Kim, Tae Kyoung
    Rogalla, Patrik
    Bathe, Oliver F.
    Knox, Jennifer J.
    CANCER, 2015, 121 (10) : 1620 - 1627
  • [34] Second-Line Therapy for Advanced NSCLC
    Weiss, Jared M.
    Stinchcombe, Thomas E.
    ONCOLOGIST, 2013, 18 (08): : 947 - 953
  • [35] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [36] Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Abbadessa, Giovanni
    Personeni, Nicola
    Porta, Camillo
    Borbath, Ivan
    Daniele, Bruno
    Van Laethem, Jean-Luc
    Van Vlieberghe, Hans
    Trojan, Jorg
    de Toni, Enrico
    Peck-Radosavljevic, Markus
    Finn, Richard S.
    Raoul, Jean-Luc
    He, Aiwu Ruth
    Lamar, Maria
    Wang, Yunxia
    Von Roemeling, Reinhard W.
    Schwartz, Brian E.
    Bruix, Jordi
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
    Oettle, H
    Arnold, D
    Esser, M
    Huhn, D
    Riess, H
    ANTI-CANCER DRUGS, 2000, 11 (08) : 635 - 638
  • [38] Second-line therapy of ovarian carcinoma
    Sevelda, P
    ONKOLOGIE, 2000, 23 (06): : 593 - 596
  • [39] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Finn, Richard S.
    Kang, Yoon-Koo
    Mulcahy, Mary
    Polite, Blase N.
    Lim, Ho Yeong
    Walters, Ian
    Baudelet, Christine
    Manekas, Demetrios
    Park, Joong-Won
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098
  • [40] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
12345